<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01657526</url>
  </required_header>
  <id_info>
    <org_study_id>116018</org_study_id>
    <nct_id>NCT01657526</nct_id>
  </id_info>
  <brief_title>Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine</brief_title>
  <official_title>An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK&#xD;
      Biologicals' NTHi candidate vaccine in adults, administered for the first time in humans.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2012</start_date>
  <completion_date type="Actual">November 25, 2013</completion_date>
  <primary_completion_date type="Actual">November 25, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of solicited local and general adverse event (AE), in all subjects, in all vaccine groups</measure>
    <time_frame>During a 7-day follow-up period (i.e. day of vaccination and 6 subsequent days) after each vaccination.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of any unsolicited AE, in all subjects, in all vaccine groups</measure>
    <time_frame>During a 30-day follow-up period (i.e. day of vaccination and 29 subsequent days) after each vaccination.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of haematological and biochemical laboratory abnormalities, in all subjects, in all vaccine groups</measure>
    <time_frame>At baseline (Screening visit) and after each vaccination.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of any serious adverse event (SAE), in all subjects, in all vaccine groups</measure>
    <time_frame>From first vaccination to study conclusion (Day 420).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of any potential Immune-Mediated Disease (pIMDs) in all subjects, in all vaccine groups</measure>
    <time_frame>From first vaccination to study conclusion (Day 420).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Humoral immune response to components of the NTHi vaccine formulations, in all subjects, in all vaccine groups</measure>
    <time_frame>Prior to each vaccination and 30 days post each vaccination.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Respiratory Disorders</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 1 of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this group will receive placebo in Step 1 of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 2 of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this group will receive placebo in Step 2 of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A)</intervention_name>
    <description>Administered intramuscularly (IM) in the deltoid region of non-dominant arm</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A)</intervention_name>
    <description>2 doses administered IM in the deltoid region of non-dominant arm</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline placebo</intervention_name>
    <description>2 doses administered IM in the deltoid region of non-dominant arm</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who, in the opinion of the investigator, can and will comply with the&#xD;
             requirements of the protocol.&#xD;
&#xD;
          -  Written informed consent obtained from the subject.&#xD;
&#xD;
          -  A male or female between, and including, 18 and 40 years of age at the time of the&#xD;
             first vaccination.&#xD;
&#xD;
          -  Healthy subjects as established by medical history, physical examination and&#xD;
             laboratory assessment before entering into the study.&#xD;
&#xD;
          -  Female subjects of non-childbearing potential may be enrolled in the study.&#xD;
&#xD;
          -  Female subjects of childbearing potential may be enrolled in the study, if the&#xD;
             subject:&#xD;
&#xD;
               -  has practiced adequate contraception for 30 days prior to vaccination, and&#xD;
&#xD;
               -  has a negative pregnancy test on the day of vaccination, and&#xD;
&#xD;
               -  has agreed to continue adequate contraception during the entire treatment period&#xD;
                  and for 2 months after completion of the vaccination series.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any investigational or non-registered product other than the study vaccines&#xD;
             within 30 days preceding the first dose of study vaccines, or planned use during the&#xD;
             study period.&#xD;
&#xD;
          -  Concurrently participating in another clinical study, at any time during the study&#xD;
             period, in which the subject has been or will be exposed to an investigational or a&#xD;
             non-investigational vaccine/product.&#xD;
&#xD;
          -  Planned administration/administration of a vaccine/product not foreseen by the study&#xD;
             protocol in the period starting 30 days before the first vaccine dose and ending 30&#xD;
             days after the last dose of vaccines.&#xD;
&#xD;
          -  Previous vaccination with a vaccine containing NTHi antigens.&#xD;
&#xD;
          -  Chronic administration of immunosuppressants or other immune-modifying drugs within&#xD;
             six months prior to the first vaccine dose, or equivalent. Topical steroids are&#xD;
             allowed.&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products within the 3 months&#xD;
             preceding the first dose of study vaccines or planned administration during the study&#xD;
             period.&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on&#xD;
             medical history and physical examination.&#xD;
&#xD;
          -  Laboratory evidence of clinically significant haematological (complete blood cell&#xD;
             count [Red Blood Cells (RBC), White Blood Cells (WBC)], WBC differential count,&#xD;
             platelets count and haemoglobin level) and biochemical (Alanine Aminotransferase&#xD;
             [ALT], Aspartate Aminotransferase [AST], creatinine and lactate dehydrogenase [LDH])&#xD;
             abnormalities as per the opinion of the investigator based on the local laboratory&#xD;
             normative data.&#xD;
&#xD;
          -  Acute disease and/or fever at the time of enrolment.&#xD;
&#xD;
          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal&#xD;
             functional abnormality, as determined by physical examination or laboratory screening&#xD;
             tests.&#xD;
&#xD;
          -  History of or current condition preventing intramuscular injection as bleeding or&#xD;
             coagulation disorder.&#xD;
&#xD;
          -  Malignancies within previous 5 years (excluding non-melanic skin cancer) and&#xD;
             lymphoproliferative disorders.&#xD;
&#xD;
          -  Pregnant or lactating female.&#xD;
&#xD;
          -  Female planning to become pregnant or planning to discontinue contraceptive&#xD;
             precautions.&#xD;
&#xD;
          -  History of chronic alcohol consumption and/or drug abuse.&#xD;
&#xD;
          -  Any other condition that the investigator judges may interfere with study findings.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>August 2, 2012</study_first_submitted>
  <study_first_submitted_qc>August 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2012</study_first_posted>
  <last_update_submitted>May 12, 2017</last_update_submitted>
  <last_update_submitted_qc>May 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy adults</keyword>
  <keyword>Safety</keyword>
  <keyword>Reactogenicity</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Non-typeable H. Influenzae (NTHi)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

